Mercks

[ad_1] Pfizer (NYSE:PFE) and Merck (NYSE:MRK) compete head-to-head in the pneumococcal vaccine market. While Pfizer’s Prevnar 13 remains the best seller, both companies have newer vaccines on the market. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Pfizer will profit not just